New Frontier Minerals (ASX:NFM) Reports Q1 2025 Highlights and Strategic Partnerships
New Frontier Minerals (ASX:NFM) reports Q1 2025 achievements, including exploration milestones, strategic alliance with Austral Resources, and asset sales.
Tag: Earnings Reports
Rent.com.au Limited (ASX:RNT) Releases Q3 FY25 Activities Report
Rent.com.au Limited (ASX:RNT) releases Q3 FY25 report, highlighting financial performance and a $1.7m entitlement issue.
The Star Entertainment Group (ASX:SGR) Releases Q3 FY25 Report
The Star Entertainment Group (ASX:SGR) reports a 9% revenue decline in Q3 FY25 and announces strategic investments to bolster liquidity.
Starpharma (ASX:SPL) Announces Q3 FY25 Activities Report
Starpharma (ASX:SPL) announces Q3 FY25 report with advancements in partnerships, product launches, and financial performance.
Omni Bridgeway Limited (ASX:OBL) Reports Record FY25 Investment Performance
Omni Bridgeway (ASX:OBL) reports record FY25 proceeds, completes Fund 9 transaction, and appoints new Head of Capital Formation.
MedAdvisor Limited (ASX:MDR) Releases 3Q FY25 Financial Update
MedAdvisor Limited (ASX:MDR) reports a significant decrease in 3Q FY25 revenue, announces cost-cutting measures and strategic initiatives.
betr Entertainment Limited (ASX:BBT) Announces Equity Raising and PointsBet Acquisition Proposal
betr Entertainment Limited (ASX:BBT) raises A$130 million to fund the acquisition of PointsBet, targeting over A$40 million in annual cost synergies.
Paradigm Biopharmaceuticals Ltd (ASX:PAR) Announces Phase 3 Trial Launch and Financial Update
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
4DMedical Limited (ASX:4DX) Reports 103% Revenue Growth and Strategic Milestones
4DMedical Limited (ASX:4DX) achieves 103% YTD revenue growth and secures key strategic partnerships in Q3 FY2025.
Immutep Limited (ASX:IMM) Reports Q3 FY25 Milestones and Financial Position
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.